Sign up to save your podcasts
Or
Share Lumithera CEO Discusses FDA Authorization for Veleda for Dry AMD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Lumithera CEO Discusses FDA Authorization for Veleda for Dry AMD
The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Eyewire NewsThe CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle.
Learn more about your ad choices. Visit megaphone.fm/adchoices